- Home
- ACIU vs STRO Comparison
ACIU vs STRO Comparison
Compare ACIU & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- STRO
- Stock Information
- Founded
- ACIU 2003
- STRO 2003
- Country
- ACIU Switzerland
- STRO United States
- Employees
- ACIU N/A
- STRO N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACIU Health Care
- STRO Health Care
- Exchange
- ACIU Nasdaq
- STRO Nasdaq
- Market Cap
- ACIU 332.4M
- STRO 172.8M
- IPO Year
- ACIU 2016
- STRO 2018
- Fundamental
- Price
- ACIU $2.64
- STRO $1.90
- Analyst Decision
- ACIU Strong Buy
- STRO Strong Buy
- Analyst Count
- ACIU 2
- STRO 7
- Target Price
- ACIU $12.00
- STRO $12.14
- AVG Volume (30 Days)
- ACIU 132.5K
- STRO 1.4M
- Earning Date
- ACIU 11-05-2024
- STRO 11-13-2024
- Dividend Yield
- ACIU N/A
- STRO N/A
- EPS Growth
- ACIU N/A
- STRO N/A
- EPS
- ACIU N/A
- STRO N/A
- Revenue
- ACIU $48,505,404.00
- STRO $160,955,000.00
- Revenue This Year
- ACIU $85.33
- STRO N/A
- Revenue Next Year
- ACIU $80.69
- STRO N/A
- P/E Ratio
- ACIU N/A
- STRO N/A
- Revenue Growth
- ACIU 4097200.00
- STRO 230.90
- 52 Week Low
- ACIU $2.25
- STRO $1.70
- 52 Week High
- ACIU $5.14
- STRO $6.13
- Technical
- Relative Strength Index (RSI)
- ACIU 27.22
- STRO 28.52
- Support Level
- ACIU $2.63
- STRO $1.70
- Resistance Level
- ACIU $3.07
- STRO $1.93
- Average True Range (ATR)
- ACIU 0.15
- STRO 0.20
- MACD
- ACIU -0.04
- STRO -0.01
- Stochastic Oscillator
- ACIU 8.96
- STRO 12.60
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.